Trial · NCT02174731
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 | Roxadustat | 0.77 | Standard Error 0.041 | g/dL | |
| Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 | Epoetin Alfa | 0.68 | Standard Error 0.040 | g/dL | |
| Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8-Week Evaluation Period | Roxadustat | 0.88 | Standard Error 0.044 | g/dL | |
| Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8-Week Evaluation Period | Epoetin Alfa | 0.74 | Standard Error 0.043 | g/dL | |
| Proportion of Total Time of Hb Within the Interval of >=10 g/dL From Week 28 to Week 52 | Roxadustat | 0.79 | Standard Error 0.012 | proportion of total time | |
| Proportion of Total Time of Hb Within the Interval of >=10 g/dL From Week 28 to Week 52 | Epoetin Alfa | 0.76 | Standard Error 0.012 | proportion of total time | |
| Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52 | Roxadustat | 0.65 | Standard Error 0.013 | proportion of total time | |
| Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52 | Epoetin Alfa | 0.63 | Standard Error 0.012 | proportion of total time | |
| Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24 | Roxadustat | -0.38 | Standard Error 0.026 | millimole per liter | |
| Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24 | Epoetin Alfa | -0.05 | Standard Error 0.026 | millimole per liter | |
Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN) | Roxadustat | 0.80 | Standard Error 0.077 | g/dL | |
Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN) | Epoetin Alfa | 0.59 | Standard Error 0.076 | g/dL | |
| Mean Monthly IV Iron Use From Week 36 to End of Study (EOS) | Roxadustat | 58.71 | Standard Deviation 236.12 | milligram per month | |
| Mean Monthly IV Iron Use From Week 36 to End of Study (EOS) | Epoetin Alfa | 91.37 | Standard Deviation 225.64 | milligram per month | |
| Time-To-First Administration of RBC Transfusion as Rescue Therapy | Roxadustat | 6.0 | events per 100 participant years | ||
| Time-To-First Administration of RBC Transfusion as Rescue Therapy | Epoetin Alfa | 7.2 | events per 100 participant years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02174731/results